Polyene Phosphatidyl choline
ApprovedSmall molecule
Polyene Phosphatidyl choline is one of 49 small molecule programs targeting Cholestasis. It is currently in Approved.
2
Indications
2
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
676 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1Polyene Phosphatidyl choline
ZZhejiang Hisun Pharmaceutical Co. Ltd.
Approved
Byetta
AstraZenecaPreclinical
Tanzeum
GSKPreclinical
Insulin 320
Novo NordiskPreclinical
NOVOLIN R
Novo NordiskPreclinical
Dostinex
PfizerPreclinical
Cipro
BayerPreclinical
Golytely
BayerPreclinical
Lantus
SanofiPreclinical
Lixisenatide
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cholestasis1 trial
Type 2 Diabetes Mellitus1 trial
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
Not yet recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT07303803·300 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details